Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 54: 1325-1330, 2008. First published June 12, 2008; 10.1373/clinchem.2008.103234
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
clinchem.2008.103234v1
54/8/1325    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Scheffer, P. G.
Right arrow Articles by Heine, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Scheffer, P. G.
Right arrow Articles by Heine, R. J.
Related Collections
Right arrow Lipids, Lipoproteins, and Cardiovascular Risk Factors
(Clinical Chemistry. 2008;54:1325-1330.)
© 2008 American Association for Clinical Chemistry, Inc.

Lipids, Lipoproteins, and Cardiovascular Risk Factors

Increased Plasma Apolipoprotein C-III Concentration Independently Predicts Cardiovascular Mortality: The Hoorn Study

Peter G. Scheffer1,4,a, Tom Teerlink1,4, Jacqueline M. Dekker2, Griët Bos2, Giel Nijpels2, Michaela Diamant3,4, Piet J. Kostense5, Coen D. A. Stehouwer6 and Robert J. Heine3,4

1 Metabolic Laboratory, Department of Clinical Chemistry, VU University Medical Center, Amsterdam;2 EMGO Institute, VU University Medical Center, Amsterdam;3 Department of Endocrinology/Diabetes Center, VU University Medical Center, Amsterdam;4 Institute for Cardiovascular Research, VU University Medical Center, Amsterdam;5 Department of Clinical Epidemiology and Biostatistics, VU University Medical Center, Amsterdam;6 Department of Medicine, Division of General Internal Medicine, University Hospital Maastricht, Maastricht, The Netherlands.

aAddress correspondence to this author at: VU University Medical Center, Department of Clinical Chemistry, P.O. Box 7057, 1007 MB, Amsterdam, The Netherlands. Fax +31-204443895; e-mail p.scheffer{at}vumc.nl.

Background: Hypertriglyceridemia is a cardiovascular risk factor. Apolipoprotein C-III (apoC-III) is an important determinant of the catabolic rate of triglyceride-rich lipoproteins. The aim of this study was to investigate the prognostic value of plasma apoC-III concentrations for cardiovascular mortality.

Methods: We performed this prospective study in 2244 subjects (ages 49–77 years) who participated in the Hoorn Study. During a mean follow-up of 15 years, 504 individuals died: 231 of cardiovascular disease, 180 of cancer, and 93 of other causes. Cardiovascular disease risk factors and plasma apoC-III concentrations were measured at baseline.

Results: The age- and sex-adjusted plasma apoC-III concentration was prospectively associated with cardiovascular mortality (P < 0.001). After adjustment for traditional risk factors, including fasting triglycerides, the hazard ratio (95% CI) for cardiovascular death between the highest and the lowest quartile of apoC-III was 1.85 (1.02–3.38). High concentrations of apoC-III did not appear to be associated with noncardiovascular mortality.

Conclusions: In this general population cohort, a high apoC-III concentration in plasma, independently of fasting triglycerides and other traditional risk factors, predicts cardiovascular mortality.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the American Association for Clinical Chemistry.